The study of diagnosis and treatment of facial palsy
Phase 4
Recruiting
- Conditions
- Facial palsy caused by viral peripheral neuritisHSV-1, VZV, Facial palsyD005158
- Registration Number
- JPRN-jRCT1031190235
- Lead Sponsor
- Wasano Koichiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 564
Inclusion Criteria
1. Facial palsy patients 7 days or less after onset
2. Moderate or severe facial palsy patients(Yanagihara score is 18 and under)
3. Obtained written informed consent
Exclusion Criteria
Patients who are contraindications or relative contraindications to administration of test drug, prednisolone.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recovery rate of facial palsy.
- Secondary Outcome Measures
Name Time Method Improvement rate of facial palsy<br>Incidence of adverse event<br>Developing diagnostic method of causing virus<br>Evaluation about quality of life relating facial palsy
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie viral-induced facial palsy and potential therapeutic targets for intervention?
How does the novel diagnostic method in JPRN-jRCT1031190235 compare to standard-of-care approaches for HSV-1 and VZV-related facial palsy?
Which biomarkers are associated with response prediction and patient selection in viral peripheral neuritis-induced facial palsy?
What are the known or potential adverse events associated with antiviral therapies in JPRN-jRCT1031190235 and their management strategies?
What combination approaches or competitor drugs are being explored for treating HSV-1 and VZV-induced facial palsy in phase IV trials?